SCHEMBL2303349

SCHEMBL2303349

c1cc(C2CNCCC23CCNCC3)ccn1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.38
HPGD P15428 1/20 0.37
CYP2C19 P33261 3/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
ADRB2 P07550 1/20 0.35
NCF1 P14598 1/20 0.35
PLD1 Q13393 1/20 0.35
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
RECQL P46063 1/20 0.33
CYP1A2 P05177 1/20 0.31
MKNK1 Q9BUB5 1/20 0.30
MKNK2 Q9HBH9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11888742 0.90 CYP2D6 (0.36) CYP2D6HPGDCYP2C19ALDH1A1CYP3A4
SCHEMBL3333534 0.86 CYP2D6 (0.33) CYP2D6HPGDCYP2C19ALDH1A1CYP3A4
SCHEMBL17135722 0.81 OPRM1 (0.44) HPGDALDH1A1CYP3A4CYP2C9TSHR
SCHEMBL29077955 0.81 CYP2D6 (0.37) CYP2D6HPGDCYP2C19ALDH1A1CYP3A4
SCHEMBL29077956 0.81 CYP2D6 (0.37) CYP2D6HPGDCYP2C19ALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL25431015 0.79 CYP2D6 (0.36) CYP2D6HPGDCYP2C19ALDH1A1CYP3A4
SCHEMBL15568523 0.78 TAAR1 (0.41) HPGDALDH1A1CYP3A4CYP2C9
SCHEMBL31478425 0.72 POLB (0.40)
SCHEMBL15571072 0.71 TAAR1 (0.39) HPGDALDH1A1CYP3A4CYP2C9
SCHEMBL6132475 0.70 ADRB1 (0.42) CYP2D6CYP2C19ALDH1A1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152158-A1 Substituted Disulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-06-17 US claimed
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8232288-B2 Substituted benzimidazoles, benzothiazoles and benzoxazoles GRUENENTHAL GMBH (DE) 2012-07-31 US disclosed
EP-2350003-A1 SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS Grünenthal GmbH (DE) 2011-08-03 EP disclosed
US-20100152158-A1 Substituted Disulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-06-17 US disclosed
WO-2010051977-A1 SUBSTITUTED DISULFONAMIDES AS BRI-MODULATORS Grünenthal GmbH (DE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152158-A1 Substituted Disulfonamide Compounds BDKRB1, BDKRB2, BRS3 CYP2D6 1247/4885HPGD 2320/4885CYP2C19 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.